Biocytogen, headquartered in Beijing, China, was founded in 2008. Currently, Biocytogen has four branches located in Beijng (Beijing Biocytogen Co.,Ltd), Haimen /Jiangsu (Biocytogen Jiangsu Co.,Ltd), Shanghai (Biocytogen Shanghai Co.,Ltd) and Wakefield/Boston (Biocytogen Boston Corporation), respectively.
With over seven hundred employees worldwide, Biocytogen provides our clients with high quality services, including generation of custom gene-modified animal models/cell lines, animal model breeding and production, preclinical study services focusing on immuno-oncology and therapeutic antibody R&D services.
In the past 10 years, Biocytogen has become one of the global leaders in gene modified animal model production with its highly reliable and efficient technology platforms, including mouse ESC/HR and our innovative CRISPR-based Extreme Genome Editing (EGE) system. EGE technology is a standout platform that increases large fragment knockin efficiencies by 10-20-fold. Biocytogen generates over 1,500 gene modified mouse/rat models/cell lines for our clients every year.
Biocytogen’s I/O-oriented preclinical evaluation services are strongly supported by our unique models which range from single and double humanized immune checkpoint mouse models (e.g. B-hPD-1 mice), to human immune system reconstituted immune-deficient mice (B-NDG mice). These models are extremely useful for in vivo efficacy studies as they are excellent tools to evaluate antibody and compound candidates targeting specific human immune checkpoints at various stages of drug development.
Moreover, our therapeutic antibody R&D service integrates Biocytogen’s novel high throughput hybridoma technology and animal model-based in vivo antibody screening platform. Working closely with our customers, Biocytogen develops therapeutic antibodies against different molecular targets in a fast and cost-effective manner.
The supply of animal models for our customers is assured by our state-of-art large scale animal facility. Currently Biocytogen operates an 8,500 m2 AAALAC accredited animal facility located at Haimen, Jiangsu province. A new campus (phase II) is being developed, which will be equipped with a 30,000 m2animal facility in Haimen; our new headquarters in Beijing will also be equipped with a 12,000 m2. These developments are expected to be completed in 2019.
In the 10 years since it was founded, Biocytogen has established a global technical service network powered by our unique technical platforms, strict quality control systems, talented scientists, and an efficient and supportive administrative team. We proudly support customers from exceptional academic research institutions across the United States, Canada, Europe and Asia, including Harvard University and the NIH, as well as from world-renowned hospitals (e.g. Massachusetts General Hospital) and top pharmaceutical companies such as Amgen, BMS, GSK, Johnson and Johnson, Merck, Roche, Sanofi.